Hoth Therapeutics, Inc. (HOTH) reported in vitro data showing SARS-CoV-2 antiviral activity for its lead peptide candidate for HT-002, a therapeutic targeted for the treatment of COVID-19. The company said the data supports that HT-002 has the potential to be developed as a novel therapeutic to both prevent and treat COVID-19. The company plans to pursue further preclinical animal studies.
"We are encouraged by these extremely positive in vitro results supporting that HT-002's novel peptide could provide substantial antiviral activity against SARS-CoV-2," said Stefanie Johns, Chief Scientific Officer of Hoth Therapeutics.
Shares of Hoth Therapeutics were up nearly 60% in pre-market trade on Tuesday.
For comments and feedback contact: editorial@rttnews.com
Business News
June 12, 2026 17:14 ET Major central bank action was the focus this week in economic news. The European Central Bank became the first major central bank to move in response to the rising inflationary pressures in the backdrop of the conflict in the Middle East. In North America, the U.S. inflation and trade data as well as Canada’s central bank decision gained attention. The Chinese trade data was the main news in Asia.